Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Galecto, Inc. GLTO NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
53/100
3/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$43.67
+64%

Galecto, Inc. (GLTO) is a Biotechnology company in the Healthcare sector, currently trading at $26.62. It has a SharesGrow Score of 51/100, indicating a mixed investment profile with 3 out of 7 criteria passed.

Analyst consensus target is GLTO = $44 (+64% upside).

Valuation: GLTO trades at a trailing Price-to-Earnings (P/E) of -0.2 (S&P 500 average ~25).

Net income is $210M (loss), growing at -265.5%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $1M against $240M equity (Debt-to-Equity (D/E) ratio 0.01, conservative). Current ratio is 12.98 (strong liquidity). Debt-to-assets is 0.5%. Total assets: $261M.

Analyst outlook: 3 / 5 analysts rate GLTO as buy (60%) — moderate consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 28/100 (Fail), Future 73/100 (Pass), Income ?/100 (Fail).

$43.67
▲ 64.05% Upside
Average Price Target
Based on 5 Wall Street analysts offering 12-month price targets for Galecto, Inc., the average price target is $43.67, with a high forecast of $46.00, and a low forecast of $40.00.
Highest Price Target
$46.00
Average Price Target
$43.67
Lowest Price Target
$40.00

GLTO SharesGrow Score Overview

63/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 28/100
Gross margin is + market cap
FUTURE 73/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — GLTO

✓
VALUE Pass
100/100
GLTO trades at a trailing Price-to-Earnings (P/E) of -0.2 (S&P 500 average ~25). Analyst consensus target is $44, implying +65.3% from the current price $27. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
GLTO: +0%/yr revenue is, -265.5%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet GLTO: Debt-to-Equity (D/E) ratio 0.01 (conservative), Current ratio is 12.98 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
28/100
GLTO: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
73/100
Analyst outlook: 3 / 5 analysts rate GLTO as buy (60%). Analyst consensus target is $44 (+65.3% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range2.01-38.325
Volume1.09K
Avg Volume (30D)393.98K
Market Cap$42.52M
Beta (1Y)1.57
Share Statistics
EPS (TTM)-3.98
Shares Outstanding$2.33M
IPO Date2020-10-29
Employees5
CEOLori C. Firmani
Financial Highlights & Ratios
Gross Profit$-174.31M
EBITDA$-36.53M
Net Income$-209.84M
Operating Income$-36.56M
Total Cash$257.62M
Total Debt$1.41M
Net Debt$-256.22M
Total Assets$260.53M
Price / Earnings (P/E)-6.7
Analyst Forecast
1Y Price Target$45.00
Target High$46.00
Target Low$40.00
Upside+69.0%
Rating ConsensusBuy
Analysts Covering5
Buy 60% Hold 40% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS36322Q2066

Price Chart

Track all markets on TradingView
GLTO
Galecto, Inc. ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
2.01 52WK RANGE 38.33

People Also View

RVMD
RVMD
Revolution Medicines, Inc.
$152.54
+3.76%
 CNTA
CNTA
Centessa Pharmaceuticals plc
$39.61
+0.05%
 TERN
TERN
Terns Pharmaceuticals, Inc.
$52.71
+0.06%
 EWTX
EWTX
Edgewise Therapeutics, Inc.
$33.70
+1.63%
 DAWN
DAWN
Day One Biopharmaceuticals, Inc.
$21.47
+0.05%
 AMLX
AMLX
Amylyx Pharmaceuticals, Inc.
$17.12
+1.18%
 MLTX
MLTX
MoonLake Immunotherapeutics
$18.02
-4.05%
 GLUE
GLUE
Monte Rosa Therapeutics, Inc.
$18.23
+4.17%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message